What is Regen Biopharma's earnings per share (EPS)?

Regen Biopharma (RGBPP) reported diluted earnings per share of -$0.05 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Regen Biopharma Financials

RGBPP

Trailing 12 months to June 30, 2026

Revenue $237K 0.0% YoY

Net Income -$1.2M -22.7% YoY

EPS (Diluted) -$0.05 FY2025 annual

Free Cash Flow Not reported for the trailing 12 months

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Jun 30, 2026 Reported Aug 17, 2026 Currency USD FYE September

Regen Biopharma (RGBPP) reported $237K in revenue over the twelve months to Jun 30, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI RGBPP FY2025 2026-08-15

Flat revenue and repeated cash burn show this business currently operates by cutting spend and raising financing, not scaling sales.

Across the last three years, revenue stayed near $237K even as the operating loss nearly halved to -$339K, pointing to expense reduction rather than business expansion. The clearest lever was R&D falling from $212K to $11.7K, so the smaller loss reflects a lower spending base, not a bigger engine of sales.

Operating cash flow of -$384K was close to the operating loss of -$339K, a useful earnings-quality signal: the reported loss was not mainly an accounting artifact. With revenue still minimal, that means the core operation itself is using cash rather than being dragged down by one-off accruals.

The balance sheet shows external financing is doing the heavy lifting: year-end cash was only $69.6K, while financing inflows were $452K. A 0.04x current ratio and negative equity make this look more like a company rolling short-term obligations forward than one funded by internally generated resources.

Financial Health Signals

Financial health score not available

Regen Biopharma does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/7

Regen Biopharma passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Regen Biopharma reported a net loss of $1.3M while operations used $384K of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Regen Biopharma reported an operating loss of $339K against $158K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$237K

YoY0.0%

5Y CAGR+16.5%

10Y CAGR+2.1%

Regen Biopharma generated $237K in revenue in fiscal year 2025. That is unchanged from the prior year.

Net Income

-$1.3M

YoY-90.7%

Regen Biopharma reported -$1.3M in net income in fiscal year 2025. This represents a decrease of 90.7% from the prior year.

EPS (Diluted)

-$0.05

Regen Biopharma earned -$0.05 per diluted share (EPS) in fiscal year 2025.

EBITDA

Not reported for fiscal year 2025.

Cash & Balance Sheet

Cash & Debt

$70K

YoY+9614.4%

10Y CAGR+6.1%

Regen Biopharma held $70K in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

108M

Regen Biopharma had 108M shares outstanding in fiscal year 2025.

Free Cash Flow

Not reported for fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending

$12K

YoY-92.4%

5Y CAGR-2.5%

10Y CAGR-27.2%

Regen Biopharma invested $12K in research and development in fiscal year 2025. This represents a decrease of 92.4% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

Capital Expenditures

Not reported for fiscal year 2025.

RGBPP Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

RGBPP quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13
Revenue	$237K	$237K0.0%	$237K0.0%	$237K+88.5%	$126K+105.1%	$61K-44.4%	$110K0.0%	$110K+10.0%	$100K-9.1%	$110K+10.0%	$100K-47.9%	$192K	$0	N/A
R&D Expenses	$224K	$12K-92.4%	$154K-27.6%	$212K+34.2%	$158K+330.8%	$37K+176.3%	$13K-70.9%	$46K-87.8%	$374K-67.4%	$1.1M+71.3%	$671K+137.7%	$282K+1082.8%	$24K+184.3%	$8K
SG&A Expenses	$296K	$75K	$0	$0-100.0%	$28K-76.5%	$119K-52.1%	$250K-50.1%	$501K-32.7%	$744K-9.5%	$822K	N/A	N/A	N/A	$263K
Operating Income	-$804K	-$339K+18.9%	-$417K+39.3%	-$687K-102.3%	-$340K-69.2%	-$201K+4.1%	-$209K	N/A	N/A	-$2.5M	N/A	N/A	N/A	-$320K
Interest Expense	$170K	$158K+118.5%	$72K+23.7%	$59K-57.8%	$139K-56.1%	$316K-5.2%	$333K+13.0%	$295K+13.9%	$259K+162.2%	$99K+255.1%	$28K+28.3%	$22K+880.5%	$2K	$0
Income Tax	$0	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$1.2M	-$1.3M-90.7%	-$668K-157.8%	$1.2M-52.7%	$2.4M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$355K
EPS (Diluted)	—	-$0.05	-$0.16-155.2%	$0.29	$0.71	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	$59K0.0%	$59K0.0%	$59K-0.5%	$59K+0.5%	$59K0.0%	$59K0.0%	$59K-0.5%	$59K
R&D Expenses	$0-100.0%	$2K-98.9%	$210K+1691.0%	$12K	$0	$0	$0-100.0%	$34K
SG&A Expenses	$14K-56.9%	$32K-86.2%	$232K+1206.5%	$18K-42.2%	$31K+130.0%	$13K+0.2%	$13K+134.8%	-$38K
Operating Income	$25K+116.0%	-$154K+72.1%	-$552K-348.3%	-$123K-201.9%	-$41K+64.0%	-$113K-84.7%	-$61K+28.1%	-$85K
Interest Expense	$30K+10.9%	$27K+3.1%	$27K-69.1%	$86K+248.9%	$25K+10.3%	$22K-11.9%	$25K+26.4%	$20K
Income Tax	$0	$0	$0	$0	$0	$0	$0	N/A
Net Income	-$638K-164.3%	$992K+202.5%	-$968K-69.1%	-$572K-242.2%	-$167K-764.4%	-$19K+96.2%	-$515K-94.6%	-$265K
EPS (Diluted)	$0.00	$0.00	-$0.01	-$0.02	-$0.01	$0.00+100.0%	-$0.13	-$0.06

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

RGBPP Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

RGBPP quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13
Total Assets	$275K+70.5%	$161K-54.4%	$354K-36.7%	$559K-53.9%	$1.2M+883.9%	$123K+24.3%	$99K-52.6%	$209K-77.9%	$944K+195.7%	$319K+44.9%	$220K+1969.0%	$11K-90.8%	$116K
Current Assets	$275K+91.6%	$143K+9.4%	$131K-61.0%	$336K-66.2%	$994K+863.1%	$103K+30.5%	$79K+85.0%	$43K-91.1%	$478K+130.7%	$207K+234.2%	$62K+482.4%	$11K-90.8%	$116K
Cash & Equivalents	$70K+9614.4%	$716-99.4%	$121K+136.4%	$51K-93.0%	$727K	$0-100.0%	$8K-2.0%	$8K-97.0%	$270K+987.6%	$25K-35.7%	$39K	$0-100.0%	$116K
Accounts Receivable	$205K+115.9%	$95K	$0-100.0%	$254K+19.3%	$213K+106.6%	$103K+45.0%	$71K	$0	$0-100.0%	$83K	N/A	N/A	N/A
Total Liabilities	$6.6M+21.9%	$5.4M-1.5%	$5.5M-36.5%	$8.6M-41.5%	$14.7M+97.1%	$7.5M-32.2%	$11.0M+18.0%	$9.3M+50.6%	$6.2M+583.6%	$906K+185.3%	$318K+126.4%	$140K	$0
Current Liabilities	$6.6M+21.9%	$5.4M+1.3%	$5.3M-38.2%	$8.6M-41.5%	$14.7M+97.1%	$7.5M-32.2%	$11.0M+26.9%	$8.7M+47.9%	$5.9M+633.6%	$799K+151.6%	$318K+126.4%	$140K	$0
Total Equity	-$6.3M-20.4%	-$5.2M-2.2%	-$5.1M+36.5%	-$8.0M+40.4%	-$13.5M-83.9%	-$7.3M+32.8%	-$10.9M-19.6%	-$9.1M-73.7%	-$5.3M-794.8%	-$587K-503.9%	-$97K+25.0%	-$130K-211.8%	$116K
Retained Earnings	-$21.7M-6.2%	-$20.4M-3.4%	-$19.7M+5.5%	-$20.9M+10.5%	-$23.3M-40.8%	-$16.6M+17.1%	-$20.0M-14.6%	-$17.5M-37.0%	-$12.7M+37.0%	-$20.2M-62.1%	-$12.5M-875.6%	-$1.3M-144.8%	-$522K

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$288K+10.5%	$260K+9.8%	$237K-13.7%	$275K+39.5%	$197K+16.1%	$169K-11.5%	$191K+18.8%	$161K
Current Assets	$288K+10.5%	$260K+9.8%	$237K-13.7%	$275K+53.3%	$179K+18.0%	$152K-12.6%	$174K+21.2%	$143K
Cash & Equivalents	$239-11.8%	$271-94.1%	$5K-93.4%	$70K+3849.7%	$2K0.0%	$2K+1204.4%	$135-81.1%	$716
Accounts Receivable	$287K+10.6%	$260K+11.8%	$232K+13.4%	$205K+15.7%	$177K+18.3%	$150K+22.4%	$122K+28.9%	$95K
Total Liabilities	$6.2M+9.7%	$5.6M-17.5%	$6.8M+3.9%	$6.6M+9.0%	$6.0M+2.5%	$5.9M0.0%	$5.9M+9.1%	$5.4M
Current Liabilities	$6.2M+9.7%	$5.6M-17.5%	$6.8M+3.9%	$6.6M+9.0%	$6.0M+2.5%	$5.9M0.0%	$5.9M+9.1%	$5.4M
Total Equity	-$5.9M-9.7%	-$5.4M+18.5%	-$6.6M-4.6%	-$6.3M-8.0%	-$5.8M-2.1%	-$5.7M-0.3%	-$5.7M-8.8%	-$5.2M
Retained Earnings	-$22.3M-2.9%	-$21.7M+4.4%	-$22.7M-4.5%	-$21.7M-2.7%	-$21.1M-0.8%	-$21.0M-0.1%	-$20.9M-2.5%	-$20.4M

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

RGBPP Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

RGBPP quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13
Operating Cash Flow	-$445K	-$384K+49.0%	-$752K-332.1%	-$174K+71.3%	-$607K+46.3%	-$1.1M-6165.6%	$19K+103.9%	-$482K	N/A	-$1.9M	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	$25K-94.9%	$495K	$0-100.0%	$50K+968.5%	-$6K	$0	N/A	N/A	N/A	N/A
Financing Cash Flow	$444K	$452K-28.3%	$631K+159.0%	$244K+359.2%	-$94K-106.9%	$1.4M+5243.8%	-$27K-106.1%	$432K	N/A	$2.1M	N/A	N/A	N/A	$400K

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	-$24K+61.9%	-$63K+68.1%	-$198K-23.7%	-$160K-185.8%	-$56K+44.7%	-$101K-52.5%	-$66K+68.0%	-$207K
Financing Cash Flow	$24K-59.2%	$59K-55.7%	$133K-41.6%	$228K+307.0%	$56K-45.6%	$103K+56.3%	$66K-55.0%	$146K

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

RGBPP Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

RGBPP quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13
Operating Margin	-143.1%	-176.4%	-290.4%	-270.6%	-328.1%	-190.3%	N/A	N/A	-2282.6%	N/A	N/A	N/A	N/A
Net Margin	-538.8%	-282.5%	488.9%	1946.8%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-306.3%
Return on Assets	-464.1%-49.2pp	-414.9%-741.9pp	327.1%-110.1pp	437.1%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-306.3%
Current Ratio	0.040.0x	0.030.0x	0.020.0x	0.040.0x	0.07+0.1x	0.010.0x	0.010.0x	0.00-0.1x	0.08-0.2x	0.26+0.1x	0.20+0.1x	0.08	N/A
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.00

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Margin	41.5%	-260.2%	-933.9%	-207.3%	-69.0%	-191.9%	-103.9%	-143.9%
Net Margin	-1079.8%	1679.4%	-1638.6%	-964.3%	-283.2%	-32.8%	-872.6%	-446.2%
Return on Assets	-221.8%-603.0pp	381.2%+789.5pp	-408.2%-199.8pp	-208.4%-123.5pp	-85.0%-73.6pp	-11.4%+257.8pp	-269.3%-104.8pp	-164.5%
Current Ratio	0.050.0x	0.050.0x	0.030.0x	0.040.0x	0.030.0x	0.030.0x	0.030.0x	0.03

Not reported in any period shown, so not listed: Gross Margin, Return on Equity, Debt-to-Equity, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Note: Shareholder equity is negative (-$6.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.04), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Ocean Biomedical Inc. OCEA

$6.8M

Appili Ther APLIF

$1.3M

Ayala Pharm ADXS

$25.7M

Galera Therapeutics, Inc. GRTX

$6.5M

Halberd Corp HALB

$637K

Where Regen Biopharma Ranks

Frequently Asked Questions

What is Regen Biopharma's annual revenue?

Regen Biopharma (RGBPP) reported $237K in total revenue for fiscal year 2025. That is unchanged from the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Regen Biopharma's revenue growing?

Regen Biopharma (RGBPP) revenue was essentially unchanged year-over-year, at $237K in fiscal year 2025 against $237K the year before.

Is Regen Biopharma profitable?

No, Regen Biopharma (RGBPP) reported a net income of -$1.3M in fiscal year 2025.

What is Regen Biopharma's operating cash flow?

Regen Biopharma (RGBPP) recorded an outflow of $384K in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Regen Biopharma's total assets?

Regen Biopharma (RGBPP) had $275K in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Regen Biopharma spend on research and development?

Regen Biopharma (RGBPP) invested $12K in research and development during fiscal year 2025.

How many shares does Regen Biopharma have outstanding?

Regen Biopharma (RGBPP) had 108M shares outstanding as of fiscal year 2025.

What is Regen Biopharma's current ratio?

Regen Biopharma (RGBPP) had a current ratio of 0.04 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Regen Biopharma's return on assets (ROA)?

Regen Biopharma (RGBPP) had a return on assets of -464.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Regen Biopharma's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Regen Biopharma (RGBPP) held $70K in cash, cash equivalents and investments, and reported an operating cash outflow of $384K over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is Regen Biopharma's debt-to-equity ratio negative or not reported?

Regen Biopharma (RGBPP) has negative shareholder equity of -$6.3M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Regen Biopharma's Piotroski F-Score?

Regen Biopharma (RGBPP) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Regen Biopharma's earnings high quality?

Regen Biopharma (RGBPP) reported a net loss of $1.3M while operations used $384K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Regen Biopharma cover its interest payments?

Regen Biopharma (RGBPP) reported an operating loss of $339K against $158K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.